Notal Vision Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Notal Vision Ltd.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
DigiSight Technologies Inc.'s cloud-based Paxos platform enables patients with acute ophthalmic conditions to self-administer 10 functional tests, ranging from visual acuity to color discrimination, using an application on a smartphone, tablet or other mobile device.
A mere seven years ago, before the approval of Visudyne photodynamic therapy, patients losing their vision to age-related macular degeneration (AMD) were told that there was nothing that could be done for them. Today, AMD sufferers may choose from an assortment of drug treatments. Genentech's Lucentis will reach almost $1 billion in sales in its first year on the market, analysts predict, and it doesn't claim to do anything except slow down the progression of the disease. Moreover, the drug does this better than first-generation anti-VEGF drug Macugen. And if those options aren't enough--and they're not--a handful of start-ups developing device-based therapies are making significant progress by applying some highly innovative approaches. ScyFIX, for example, is applying electrical stimulation to halt the effects of AMD and possibly repair the damage done. NeoVista is applying radiation therapy to the back of the eye, an approach that could serve as an alternative to Lucentis and other drugs based on growth factors, which require frequent injections into the eye. Retina Implant has developed an implantable microchip that will stimulate intact nerve cells in the retina to recreate the sense of sight.
- Diagnostic Equipment & Supplies
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Other Names / Subsidiaries
- Notal Vision™, Inc